Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB

Clinical trial NCT02326285 · TERMINATED

Trial details

NCT number: NCT02326285
Sponsor: AIO-Studien-gGmbH
Status: TERMINATED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Non-squamous Non-small Cell Lung Cancer Stage II Non-squamous Non-small Cell Lung Cancer Stage IIIA Non-squamous Non-small Cell Lung Cancer Stage IIIB Activating EGFR Mutation NSCLC

Start date: 2015-11-01
Primary completion: 2017-03-28
Enrollment: 1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.